177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
NCT01842165
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
37
Enrollment
OTHER
Sponsor class
Conditions
Gastroenteropancreatic Neuroendocrine Tumors
Interventions
DRUG:
Intravenous injection of 177Lu-octreotate
Sponsor
Jules Bordet Institute